Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival
for younger patients over the last several decades has improved nearly sixfold with the …

Genomic investigations of acute myeloid leukemia (AML) have demonstrated that several
genes are recurrently mutated, leading to new genomic classifications, predictive …

Background Patients with acute myeloid leukaemia (AML) positive for internal tandem
duplication (ITD) mutations of FLT3 have poor outcomes. Quizartinib, an oral, highly potent …

Background Patients with relapsed or refractory FLT3 internal tandem duplication (FLT3-
ITD)-positive acute myeloid leukaemia have a poor prognosis, including high frequency of …

Acute myeloid leukemia (AML) is a heterogeneous group of diseases characterized by
uncontrolled proliferation of hematopoietic stem cells in the bone marrow. Malignant cell …

Background Internal tandem duplication mutations in FLT3 are common in acute myeloid
leukaemia and are associated with rapid relapse and short overall survival. The clinical …

Heterobifunctional molecules that recruit E3 ubiquitin ligases, such as cereblon, for targeted
protein degradation represent an emerging pharmacological strategy. A major unanswered …

Recent major advances in understanding the molecular basis of acute myeloid leukemia
(AML) provide a double-edged sword. Although defining the topology and key features of …

Midostaurin was recently approved by the US Food and Drug Administration for the
treatment of FLT3-mutant acute myeloid leukemia (AML). This is the first drug to receive …

Internal tandem duplication (ITD) mutations within FMS-like tyrosine kinase-3 (FLT3) occur
in up to 30% of acute myeloid leukemia (AML) patients and confer a very poor prognosis …